Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.79% | -3.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.79% | -3.12% | |||
| Cost of Revenue | 18.33% | -3.41% | |||
| Gross Profit | 9.70% | -3.08% | |||
| SG&A Expenses | 14.85% | 11.88% | |||
| Depreciation & Amortization | 0.04% | -0.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.58% | 8.95% | |||
| Operating Income | -34.65% | -52.81% | |||
| Income Before Tax | -1,492.17% | -79.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,492.17% | -79.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,492.17% | -79.84% | |||
| EBIT | -34.65% | -52.81% | |||
| EBITDA | -25.14% | -44.68% | |||
| EPS Basic | -1,474.05% | -80.39% | |||
| Normalized Basic EPS | -114.63% | -80.34% | |||
| EPS Diluted | -1,900.00% | -84.54% | |||
| Normalized Diluted EPS | -115.19% | -79.48% | |||
| Average Basic Shares Outstanding | 1.35% | 2.75% | |||
| Average Diluted Shares Outstanding | -2.71% | -1.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||